JP2008501802A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501802A5
JP2008501802A5 JP2007527639A JP2007527639A JP2008501802A5 JP 2008501802 A5 JP2008501802 A5 JP 2008501802A5 JP 2007527639 A JP2007527639 A JP 2007527639A JP 2007527639 A JP2007527639 A JP 2007527639A JP 2008501802 A5 JP2008501802 A5 JP 2008501802A5
Authority
JP
Japan
Prior art keywords
solid dispersion
pharmaceutical composition
polymer
amorphous
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007527639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501802A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/019929 external-priority patent/WO2005123076A2/en
Publication of JP2008501802A publication Critical patent/JP2008501802A/ja
Publication of JP2008501802A5 publication Critical patent/JP2008501802A5/ja
Pending legal-status Critical Current

Links

Images

JP2007527639A 2004-06-08 2005-06-08 医薬組成物 Pending JP2008501802A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57804304P 2004-06-08 2004-06-08
PCT/US2005/019929 WO2005123076A2 (en) 2004-06-08 2005-06-08 Pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012000814A Division JP5337262B2 (ja) 2004-06-08 2012-01-05 医薬組成物

Publications (2)

Publication Number Publication Date
JP2008501802A JP2008501802A (ja) 2008-01-24
JP2008501802A5 true JP2008501802A5 (enExample) 2008-07-24

Family

ID=35510250

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007527639A Pending JP2008501802A (ja) 2004-06-08 2005-06-08 医薬組成物
JP2012000814A Expired - Fee Related JP5337262B2 (ja) 2004-06-08 2012-01-05 医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012000814A Expired - Fee Related JP5337262B2 (ja) 2004-06-08 2012-01-05 医薬組成物

Country Status (18)

Country Link
US (2) US20060089385A1 (enExample)
EP (1) EP1765283A4 (enExample)
JP (2) JP2008501802A (enExample)
KR (2) KR20120039763A (enExample)
CN (2) CN1988885A (enExample)
AR (1) AR049297A1 (enExample)
AU (1) AU2005253957B2 (enExample)
BR (1) BRPI0511900A (enExample)
CA (1) CA2569310A1 (enExample)
IL (2) IL179809A (enExample)
MX (1) MXPA06014253A (enExample)
NO (1) NO20070130L (enExample)
NZ (1) NZ588471A (enExample)
RU (1) RU2373923C2 (enExample)
SG (1) SG153800A1 (enExample)
TW (1) TWI389688B (enExample)
WO (1) WO2005123076A2 (enExample)
ZA (2) ZA200700030B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69709671T2 (de) * 1996-10-18 2002-08-22 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
MY148123A (en) * 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TWI437990B (zh) * 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
WO2006130686A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors in combination with food
AU2006252553B2 (en) * 2005-06-02 2012-03-29 Merck Sharp & Dohme Corp. Combination of HCV protease inhibitors with a surfactant
WO2007016589A2 (en) 2005-08-02 2007-02-08 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CA2643688A1 (en) * 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CN101460166B (zh) * 2006-03-06 2014-11-19 Abbvie公司 用于治疗c型肝炎病毒的利托那韦组合物及其用途
AU2007227544B2 (en) 2006-03-16 2012-11-01 Vertex Pharmaceuticals Incorporated Deuterated hepatitis C protease inhibitors
AU2007226984B2 (en) * 2006-03-20 2013-02-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
AU2007226983A1 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
WO2007120595A2 (en) * 2006-04-11 2007-10-25 Novartis Ag Amines for the treatment of hcv
EP2007789B1 (en) 2006-04-11 2015-05-20 Novartis AG Spirocyclic HCV/HIV inhibitors and their uses
MX2009006806A (es) * 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
WO2008074035A1 (en) * 2006-12-27 2008-06-19 Abbott Laboratories Hcv protease inhibitors and uses thereof
CA2679028A1 (en) * 2007-02-23 2008-08-28 Avera Pharmaceuticals, Inc. Pharmaceutical formulation
DK2114924T3 (da) * 2007-02-27 2012-04-10 Vertex Pharma Co-krystaller og farmaceutiske sammensætninger omfattende disse
NZ579295A (en) * 2007-02-27 2012-03-30 Vertex Pharma Inhibitors of serine proteases
TWI494133B (zh) * 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
PL2305263T3 (pl) * 2007-06-07 2012-12-31 Novartis Ag Stabilizowane amorficzne formy mesylanu imatinibu
TW200922933A (en) * 2007-08-30 2009-06-01 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
JP5161528B2 (ja) * 2007-10-02 2013-03-13 浜松ホトニクス株式会社 パクリタキセル微粒子、パクリタキセル微粒子分散液、および、これらの製造方法
JP5149585B2 (ja) * 2007-10-02 2013-02-20 浜松ホトニクス株式会社 微粒子分散液製造方法
AU2008309589B2 (en) * 2007-10-10 2012-07-05 Novartis Ag Spiropyrrolidines and their use against HCV and HIV infection
CA2699335A1 (en) * 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg. Solid dispersion product containing n-aryl urea-based compound
EP2214682A2 (en) * 2007-11-05 2010-08-11 Vertex Pharmaceuticals Incorporated Hcv combination therapies comprising vx-950, peg-ifn and ribavirin
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
EP2328656A1 (en) * 2008-09-24 2011-06-08 Vertex Pharmaceuticals Incorporated Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis "
JP2012517478A (ja) 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤
MY160737A (en) 2009-04-03 2017-03-15 Hoffmann La Roche Propane-i-sulfonic acid {3- [5-(4-chloro-phenyl) -1h -pyrrolo [2, 3-b] pyridine-3-carbonyl] -2,4 difluoro-phenyl} - amide compositions and uses thereof
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
WO2011103932A1 (en) * 2010-02-25 2011-09-01 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg A process for the preparation of substituted prolyl peptides and similar peptidomimetics
US20120014912A1 (en) 2010-07-14 2012-01-19 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
CN103491964A (zh) * 2011-03-08 2014-01-01 扎里卡斯药品有限公司 固体分散体制剂及其使用方法
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CH707030B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
ES2529143B1 (es) 2011-10-21 2015-10-26 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc
EP2907505A3 (en) * 2011-12-29 2015-12-30 Abbvie Inc. Solid compositions comprising an HCV inhibitor
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
WO2013116339A1 (en) 2012-01-31 2013-08-08 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
RU2692779C2 (ru) 2012-02-27 2019-06-27 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтическая композиция и ее введения
ITMI20120608A1 (it) * 2012-04-13 2013-10-14 Dipharma Francis Srl Procedimento per la preparazione di un inibitore delle proteasi virali in forma amorfa
WO2013178031A1 (en) * 2012-06-01 2013-12-05 Sunshine Lake Pharma Co., Ltd. New forms of telaprevir and preparation methods thereof
EP2935245A1 (en) * 2012-12-21 2015-10-28 Sandoz AG Novel forms of telaprevir
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US9732076B2 (en) 2013-03-15 2017-08-15 Boehringer Ingelheim International Gmbh Solid oral dosage formulation of HCV inhibitor in the amorphous state
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS
CN110193013B (zh) * 2019-07-02 2022-02-08 力品药业(厦门)股份有限公司 一种去乙酰真菌环氧乙酯固体分散体及其制备方法
WO2023225029A1 (en) * 2022-05-16 2023-11-23 Day One Biopharmaceuticals, Inc. Oral liquid suspension of pan-raf kinase inhibitor
WO2024080308A1 (ja) * 2022-10-12 2024-04-18 中外製薬株式会社 ペプチド、界面活性剤及びポリマーを含む組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
JPH107558A (ja) * 1996-06-19 1998-01-13 Eisai Co Ltd 溶解性改善製剤
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
ATE400251T1 (de) * 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US6627760B1 (en) * 2001-06-25 2003-09-30 Astrazeneca Ab Amorphous compound
PL374442A1 (en) * 2001-11-14 2005-10-17 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of losartan potassium and process for their preparation
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
US6642204B2 (en) * 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20060003942A1 (en) * 2003-10-27 2006-01-05 Roger Tung Combinations for HCV treatment
TWI437990B (zh) * 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途

Similar Documents

Publication Publication Date Title
JP2008501802A5 (enExample)
RU2006147247A (ru) Фармацевтические композиции
JP2009530415A5 (enExample)
JP2009530415A (ja) 医薬組成物
TWI666020B (zh) 固體分散製劑
JP2018503595A (ja) ペプチド模倣大環状分子およびその製剤
TW201026676A (en) A method of inhibiting hepatitis C virus by combination of a 5,6-dihydro-1H-pyridin-2-one and one or more additional antiviral compounds
CN103118681A (zh) 固体组合物
AU2013358897A1 (en) Pharmaceutical compositions
WO2011063076A1 (en) Methods of treating hepatitis c virus with oxoacetamide compounds
RU2342926C2 (ru) Способ получения низкокристаллического олтипраза или аморфного олтипраза
CN103228278A (zh) 治疗hcv感染的组合疗法
CN101068829B (zh) 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
WO2018222172A1 (en) Solid dispersion formulation
WO2006132342A1 (ja) ロフルミラスト点眼液
US10308937B2 (en) Combination long acting compositions and methods for Hepatitis C
KR20170083108A (ko) C형 간염에 대한 장기 작용 약학적 조성물
JPWO2001087303A1 (ja) 水性液剤
DE602004010291T2 (de) Hcv-hemmende sulfonamide
JP2016538312A (ja) 非晶質のコビシスタットの固体分散体
JPS60166613A (ja) 肝疾患治療剤
KR20140003203A (ko) 설폰아미드계 화합물을 유효성분으로 포함하는 ｃ형 간염의 예방 또는 치료용 약학적 조성물